Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth

Journal of Neuro-Oncology

Volumn 99, Issue 2, 2010, Pages 177-185

  Takano, Shingo ^a   Kamiyama, Hiroshi ^a   Mashiko, Ryota ^a   Osuka, Satoru ^a   Ishikawa, Eiichi ^a   Matsumura, Akira ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

ACNU; Angiosuppression; Irinotecan; Malignant glioma; Metronomic treatment; Vascular endothelial growth factor; Xenografts

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1BETA; IRINOTECAN; NIMUSTINE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HYPOXEMIA; LOW DRUG DOSE; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CAMPTOTHECIN; CELL PROLIFERATION; GLIOMA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956060677     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0118-8     Document Type: Article

References (43)

1. JC Buckner JM Reid K Wright SH Kaufmann C Erlichman M Ames S Cha JR O'Fallon LJ Schaaf LL Miller 2003 Irinotecan in the treatment of glioma patients. Current and future studies of the north central cancer treatment group Cancer 97 9 suppl 2352 2358 10.1002/cncr.11304 1:CAS:528:DC%2BD3sXjvVSgsrg%3D 12712456
2. JJ Vredenburgh A Desjardins DA Reardon HS Friedman 2009 Experience with irinotecan for the treatment of malignant glioma Neuro-Oncology 11 80 91 10.1215/15228517-2008-075 1:CAS:528:DC%2BD1MXjtFKntrw%3D 18784279
3. JJ Vredenburgh A Desjardins JE Herndon II J Marcello DA Reardon JA Quinn JN Rich S Sathornsumetee S Gururangan J Sampson M Wagner L Bailey DD Bigner AH Friedman HS Friedman 2007 Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 4722 4729 10.1200/JCO.2007.12.2440 1:CAS:528:DC%2BD2sXhtlCgsLjF 17947719
4. H Kamiyama S Takano K Tsuboi A Matsumura 2005 Anti-angiogenic effects of SN38 (active metabolite of Irinotecan): inhibition of hypoxia-inducible factor 1 (HIF-1α)/vascular endothelial growth factor (VEGF) expression of Glioma and growth of endothelial cells J Cancer Res Clin Oncol 131 205 213 10.1007/s00432-004-0642-z 1:CAS:528:DC%2BD2MXhtV2ktLc%3D 15583935
5. D Hanahan G Beregers E Bergsland 2000 Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice J Clin Invest 105 1045 1047 10.1172/JCI9872 1:CAS:528:DC%2BD3cXisFOltbg%3D 10772648
6. S Takano K Tsuboi A Matsumura Y Tomono Y Mistui T Nose 2000 Expression of the angiogenic factor thymidine phosphorylase in human astrocytic tumors J Cancer Res Clin Oncol 126 145 152 10.1007/s004320050024 1:CAS:528: DC%2BD3cXktVyjs74%3D 10741908
7. K Mineura T Yanagisawa K Watanabe M Kowada N Yasui 1996 Human brain tumor O6-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy Int J Cancer 69 420 425 10.1002/(SICI)1097-0215(19961021)69:5<420::AID-IJC12>3.0.CO;2-6 1:CAS:528:DyaK28Xnt1KgtLk%3D 8900378
8. SY Ng P Gunning R Eddy P Ponte J Leavitt T Shows L Kedes 1985 Evolution of the functional human beta-actin gene and its multi-pseudogene family: conservation of noncoding regions and chromosomal dispersion of pseudogenes Mol Cell Biol 5 2720 2732 1:CAS:528:DyaL2MXmtVOqsr8%3D 3837182
9. S Takano K Tsuboi A Matsumura T Nose 2003 Anti-vascular endothelial growth factor antibody and nimustine as combined therapy: effects on tumor growth and angiogenesis in human glioblastoma xenografts Neuro-Oncology 5 1 7 1:CAS:528:DC%2BD3sXhtVajtLY%3D 12626127
10. S Takano Y Yoshii S Kondo T Maruno S Shirai T Nose 1996 Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients Cancer Res 56 2185 2190 1:CAS:528:DyaK28Xis1ektbY%3D 8616870
11. K Weindel D Marme HA Weich 1992 AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelial growth factor Biochem Biophys Res Commun 183 1167 1174 10.1016/S0006-291X(05)80313-4 1:CAS:528:DyaK3sXhvV2kt7Y%3D 1567395
12. K Nakayama S Kanzaki K Hata H Katabuchi H Okamura K Miyazaki M Fukumoto Y Takebayashi 2002 Hypoxia-inducible factor 1 alpha(HIF-1α) gene expression in human ovarian carcinoma Cancer Lett 176 215 223 10.1016/S0304-3835(01)00762- 5 1:CAS:528:DC%2BD38XmsFGktw%3D%3D 11804750
13. M Nagane K Nozue S Shimizu A Waha H Miyazaki H Kurita M Homori Y Fujioka Y Shiokawa 2009 Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma-analysis of O6-methylguanine-DNA methyltransferase status J Neurooncol 92 227 232 10.1007/s11060-008-9754-7 19037596
14. K Takakura H Abe R Tanaka K Kitamura T Miwa K Takeuchi S Yamamoto N Kageyama H Handa H Mogami A Nishimoto T Uozumi M Matsutani K Nomura 1986 Effects of ACNU and radiotherapy on malignant glioma J Neurosurg 64 53 57 10.3171/jns.1986.64.1.0053 1:STN:280:DyaL28%2FovVWgsA%3D%3D 3455717
15. J Yoshida Y Kajita T Wakabayashi 1994 Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumor resection and postoperative adjuvant therapy with interferon, ACNU and radiation Acta Neurochir (Wien) 127 55 57 10.1007/BF01808547 1:STN:280:DyaK2M%2FivVKmtg%3D%3D
16. MK Clements CB Jones M Cumming SS Daoud 1999 Antiangiogenic potential of camptothecin and topotecan Cancer Chemother Pharmacol 44 411 416 10.1007/s002800050997 1:CAS:528:DyaK1MXmsVWksr4%3D 10501915
17. KW McCrudden A Yokoi A Thosani SZ Soffer ES Kim J Huang C Manley K O'Toole DJ Yamashiro JJ Kandel W Middlesworth 2002 Topotecan is anti-angiogenic in experimental hepatoblastoma J Pediatr Surg 37 857 861 10.1053/jpsu.2002.32887 12037749
18. A Nakashio N Fujita T Tsuruo 2002 Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3 K-Akt signaling pathway Int J Cancer 98 36 41 10.1002/ijc.10166 1:CAS:528:DC%2BD38Xht1WgsLY%3D 11857382
19. JJ O'Leary RL Shapiro CJ Ren N Chuang HW Cohen M Potmesil 1999 Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model Clin Cancer Res 5 181 187 9918217
20. G Petrangolini G Pratesi M De Cesare R Supino C Pisano M Marcellini V Giordano D Laccabue C Lanzi F Zunino 2003 Antiangiogenic effects of the novel camptothecin ST1481 (Gimatecan) in human tumor xenografts Mol Cancer Res 1 863 870 1:CAS:528:DC%2BD3sXotlSjsb4%3D 14573787
21. SZ Soffer E Kim JT Moore J Huang A Yokoi C Manley K O'Toole W Middleswoth C Stolar D Yamashiro J Kandel 2001 Novel use of an established agent: topotecan is anti-angiogenic in experimental Wilms tumor J Pediatr Surg 36 1781 1784 10.1053/jpsu.2001.28823 1:STN:280:DC%2BD3MnoslalsQ%3D%3D 11733906
22. D Xiao W Tan M Li J Ding 2001 Antiangiogenic potential of 10-hydroxycamptothecin Life Sci 69 1619 1628 10.1016/S0024-3205(01)01236-X 1:CAS:528:DC%2BD3MXmsFOisbg%3D 11589502
23. T Browder CE Butterfield BM Kraling B Shi B Marshall MS O'Reilly J Folkman 2000 Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res 60 1878 1886 1:CAS:528: DC%2BD3cXisVynurk%3D 10766175
24. G Klement S Baruchel J Rak S Man K Clark DJ Hicklin P Bohlem RS Kerbel 2000 Continuous low-dose therapy with vinblastin and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity J Clin Invest 105 R15 R24 10.1172/JCI8829 1:CAS:528:DC%2BD3cXisFOlurc%3D 10772661
25. S Man G Bocci Gm Francia Sk Green S Jothy D Hanahan P Bohlen DJ Hicklin G Bergeres RS Kerbel 2002 Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water Cancer Res 62 2731 2735 1:CAS:528:DC%2BD38XjvFSmsbg%3D 12019144
26. G Bocci A Falcone A Fioravanti P Orlandi A Di Paolo G Fanelli P Viacava AG Naccarato RS Kerbel R Danesi M Del Tacca G Allegrini 2008 Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib Br J Cancer 98 1619 1629 10.1038/sj.bjc.6604352 1:CAS:528:DC%2BD1cXlvVWhsb0%3D 18443598
27. Y Ogata S Mori N Ishibashi Y Akagi M Ushijima H Murakami T Fukushima K Shirouzu 2007 Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high risk to recurrence J Exp Clin Cancer Res 26 475 482 1:CAS:528:DC%2BD1cXitFSiur4%3D 18365541
28. M Shirner 2000 Antiangiogenic chemotherapeutic agents Cancer Metastasis Rev 19 67 73 10.1023/A:1026500431505
29. S Gately R Kerbel 2001 Antiangiogenic scheduling of lower dose cancer chemotherapy Cancer J 7 427 436 1:STN:280:DC%2BD3Mnjs12jsQ%3D%3D 11693902
30. L Bello G Carrabba C Giussani V Lucini F Cerutti F Scaglione J Landre M Pluderi G Tomei R Villani RS Carroll PM Black A Bikfalvi 2001 Low-dose chemotherapy combined with an antiangiogenic drug reduces human Glioma growth in vivo Cancer Res 61 7501 7506 1:CAS:528:DC%2BD3MXnvFShsLc%3D 11606386
31. J Tuettenberg R Grobholz T Korn F Wenz R Erber P Vajkozy 2005 Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme J Cancer Res Clin Oncol 131 31 40 10.1007/s00432-004-0620-5 1:CAS:528:DC%2BD2cXhtVWjt7zN 15565458
32. DS Kong JI Lee WS Kim MJ Son DH Lim ST Kim K Park JH Kim W Eoh DH Nam 2006 A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma Oncol Rep 16 1117 1121 1:CAS:528:DC%2BD28Xht1erurbO 17016602
33. C Folkins S Man P Xu Y Shaked DJ Hicklin RS Kerbel 2007 Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors Cancer Res 67 3560 3564 10.1158/0008-5472.CAN-06-4238 1:CAS:528:DC%2BD2sXkt1Kju70%3D 17440065
34. RJ Gilbertson JN Rich 2007 Making a tumour's bed: glioblastoma stem cells and the vascular niche Nat Rev Cancer 7 733 736 10.1038/nrc2246 1:CAS:528:DC%2BD2sXhtVOnsrzM 17882276
35. A Rapisarda B Uranchimeg O Sordet Y Pommier RH Shoemaker G Melillo 2004 Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications Cancer Res 64 1475 1482 10.1158/0008-5472.CAN-03-3139 1:CAS:528:DC%2BD2cXhtleitL4%3D 14983893
36. Z Arany SY Foo Y Ma JL Ruas A Bommi-Reddy G Girnum M Cooper D Laznik J Chinsomboon SM Rangwala KH Baek A Rosenzweig BM Spiegelman 2008 HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α Nature 451 1008 1012 10.1038/nature06613 1:CAS:528: DC%2BD1cXit1ynsr8%3D 18288196
37. RK Jain 2005 Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 58 62 10.1126/science.1104819 1:CAS:528:DC%2BD2MXnvFar 15637262
38. G Allegrini FA Goulette JW Darnowski P Calabresi 2004 Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice Cancer Chemother Pharmacol 53 261 266 10.1007/s00280-003-0712-y 1:CAS:528: DC%2BD2cXos1equw%3D%3D 14658007
39. S Kaneko M Ishibashi M Kaneko 2008 Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts Cancer Sci 99 1209 1217 10.1111/j.1349-7006.2008.00790.x 1:CAS:528:DC%2BD1cXnsVOrsLk%3D 18384433
40. U Herrlinger J Rieger JP Steinbach T Nagele J Dichgans M Weller 2005 UKT-04 trial of continuous metronomic low-dose chemotherapy with methotreaxate and cyclophophamide for recurrent glioblastoma J Neuro-oncol 71 295 299 10.1007/s11060-004-1726-y 1:CAS:528:DC%2BD28XksQ%3D%3D
41. S Kesari D Schiff L Doherty DC Gigas TT Batchelor A Muzikansky A O'Neill J Drappatz AS Chen-Plotkin N Ramakrishna SE Weiss B Levy J Bradshaw J Kracher A Laforme PM Black J Folkman M Kieran PY Wen 2007 Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults Neuro-Oncology 9 354 363 10.1215/15228517-2007-006 1:CAS:528:DC%2BD2sXpt1agtrY%3D 17452651
42. G Bergers D Hanahan 2008 Modes of resistance to antiangiogenic therapy Nat Rev Cancer 8 592 603 10.1038/nrc2442 1:CAS:528:DC%2BD1cXovV2lsrk%3D 18650835
43. RK Jain DG Duda JW Clark JS Loeffler 2006 Lessons from phase III clinical trials on anti-VEGF therapy for cancer Nat Clin Pract Oncol 3 24 40 10.1038/ncponc0403 1:CAS:528:DC%2BD28XhtVynsL0%3D 16407877